1
PATENT ABSTRACTS interferon; subjecting the preliminarily purified material to Tandem Chromatography, wherein the Tandem Chromatography comprises separa- tion on a cellulose column followed by an anti- alpha-interferon monoclonal antibody affinity column; subjecting the thus purified material to isoelectric precipitation of impurities at about pH 4.0 to about pH 4.8; and purifying the inter- feron by chromatography on a high perfor- mance cation exchange column using a volatile buffer, wherein the purified interferon is non- immunogenic when administered parenterally to a human. 5196324 MONOCLONAL ANTIBODIES REACTIVE WITH A HUMAN ATHEROMA ASSOCIATED ANTIGEN Thomas Bumol, Leslie M McEvoy assigned to Eli Lilly and Company The present invention relates to a naturally oc- curring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of pat- ients with coronary artery disease. The invention also comprises antibodies reactive with the anti- gen, hybridoma cell lines that produce the anti- bodies of the inveniton, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease. 5196337 HUMAN MONOCLONAL ANTIBODY, AND ITS PRODUCTION AND USE Hiroshi Ochi, Hirosh Ohtsuka, Shinich Yokota, Hirosh Noguchi, Masazum Terashima, Ikuko Uezumi, Kenji Irie, Kanagawa, assigned to Sumitomo Chemical Company Limited; Sumitomo Pharmaceuticals Company Limite A human monoclonal antibody, which has pro- phylactic and therapeutic effect to infectious dis- eases caused by Pseudomonas aeruginosa of serotypes A and H classified under the Japanese Committee's Classification, and the epitope of which is located at the common structure in the O-antigen of Pseudomonas aeruginosa of serotypes A and H. A hybridoma producing said human monoclonal antibody, and processes for 217 preparing said hybridoma and antibody are also provided. 51~3~ RECOMBINANT VECTORS FOR HAEMOPHILUS INFLUENZAE PEPTIDES AND PROTEINS Algis Anilionis, Robert C Seid, Robert Deich, Gary W Zlomick, Bruce Green assigned to Praxis Biologics Inc Peptides and proteins related to an epitope com- prising an outer membrane protein of Haemophilus influenzae are described. The pep- tides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic tech- niques. Additionally, recombinant vectors con- taining nucleotide sequences encoding PBOMP- l and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the ex- pression of the PBOMP-I and PBOMP-2 related peptides, proteins, and fusion proteins in ap- propriate host cells. The peptides,proteins,fu- sion proteins and viruses both live and inactivated are used as immunogens in vaccine formulations to protect against H. influcnzaein- fections.The peptides,proteins and fusion pro- teinsarc also used as reagents in immunoassays as well as to prepare immunoglobulins for pas- sive immunization. Use of the nucleotide sequences encoding the PBOMP related pep- tides,proteins and fusion proteins in hybridiza- tion assays is also described. 5198334 PROTECTION OF NATURAL KILLER CELL CYTOLYTIC ACTIVITY IN PERIPHERAL BLOOD MONONUCLEAR CELLS Kam H Leung assigned to Terumo Corporation Leucinol, phenylalaninol and benzamide pro- tect against loss of Natural Killer activity when Peripheral Blood Mononuclear Cells are treated with an ester of an amino acid or dipeptide or an amide of an amino acid prior to incubation with IL-2 to generate Lymphokine-Activated Killer activity.

5198334 Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells

Embed Size (px)

Citation preview

Page 1: 5198334 Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells

PATENT ABSTRACTS

interferon; subjecting the preliminarily purified material to Tandem Chromatography, wherein the Tandem Chromatography comprises separa- tion on a cellulose column followed by an anti- alpha-interferon monoclonal antibody affinity column; subjecting the thus purified material to isoelectric precipitation of impurities at about pH 4.0 to about pH 4.8; and purifying the inter- feron by chromatography on a high perfor- mance cation exchange column using a volatile buffer, wherein the purified interferon is non- immunogenic when administered parenterally to a human.

5196324

M O N O C L O N A L A N T I B O D I E S R E A C T I V E W I T H A H U M A N A T H E R O M A A S S O C I A T E D

A N T I G E N

Thomas Bumol, Leslie M McEvoy assigned to Eli Lilly and Company

The present invention relates to a naturally oc- curring, minimally modified LDL antigen which is present in human atherosclerotic lesions as well as in the serum of a high percentage of pat- ients with coronary artery disease. The invention also comprises antibodies reactive with the anti- gen, hybridoma cell lines that produce the anti- bodies of the inveniton, and methods for using the antibodies in the diagnosis and treatment of atherosclerotic disease.

5196337

H U M A N M O N O C L O N A L A N T I B O D Y , A N D ITS

P R O D U C T I O N A N D U S E

Hiroshi Ochi, Hirosh Ohtsuka, Shinich Yokota, Hirosh Noguchi, Masazum Terashima, Ikuko Uezumi, Kenji Irie, Kanagawa, assigned to Sumitomo Chemical Company Limited; Sumitomo Pharmaceuticals Company Limite

A human monoclonal antibody, which has pro- phylactic and therapeutic effect to infectious dis- eases caused by Pseudomonas aeruginosa of serotypes A and H classified under the Japanese Committee's Classification, and the epitope of which is located at the common structure in the O-antigen of Pseudomonas aeruginosa of serotypes A and H. A hybridoma producing said human monoclonal antibody, and processes for

217

preparing said hybridoma and antibody are also provided.

5 1 ~ 3 ~

R E C O M B I N A N T V E C T O R S F O R H A E M O P H I L U S I N F L U E N Z A E

P E P T I D E S A N D P R O T E I N S

Algis Anilionis, Robert C Seid, Robert Deich, Gary W Zlomick, Bruce Green assigned to Praxis Biologics Inc

Peptides and proteins related to an epitope com- prising an outer membrane protein of Haemophilus influenzae are described. The pep- tides and proteins can be prepared by methods including novel and improved methods of purification from H. influenzae cultures, and by recombinant DNA and chemical synthetic tech- niques. Additionally, recombinant vectors con- taining nucleotide sequences encoding PBOMP- l and PBOMP-2 related peptides, proteins and fusion proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the ex- pression of the PBOMP-I and PBOMP-2 related peptides, proteins, and fusion proteins in ap- propriate host cells. The peptides, proteins, fu- sion proteins and viruses both live and inactivated are used as immunogens in vaccine formulations to protect against H. influcnzae in- fections. The peptides, proteins and fusion pro- teins arc also used as reagents in immunoassays as well as to prepare immunoglobulins for pas- sive immunization. Use of the nucleotide sequences encoding the PBOMP related pep- tides, proteins and fusion proteins in hybridiza- tion assays is also described.

5198334

P R O T E C T I O N O F N A T U R A L K I L L E R C E L L C Y T O L Y T I C A C T I V I T Y IN P E R I P H E R A L

B L O O D M O N O N U C L E A R C E L L S

Kam H Leung assigned to Terumo Corporation

Leucinol, phenylalaninol and benzamide pro- tect against loss of Natural Killer activity when Peripheral Blood Mononuclear Cells are treated with an ester of an amino acid or dipeptide or an amide of an amino acid prior to incubation with IL-2 to generate Lymphokine-Activated Killer activity.